Management of Subclinical Hyperthyroidism in Older Adults

Diagnostic Approach

Repeat thyroid function testing, adding free T3 to TSH and free T4, to confirm that the condition is truly subclinical rather than overt hyperthyroidism. 3
A suppressed TSH < 0.1 mIU/L indicates more severe suppression than a TSH of 0.1–0.4 mIU/L and should drive treatment decisions. 4
In patients ≥ 65 years, approximately 50 % of suppressed TSH values normalize spontaneously over months to years, while progression to overt hyperthyroidism occurs only in a minority. 3
Thyroid scintigraphy (Tc‑99 or I‑123) is the first‑line etiologic test; it identifies autonomous thyroid tissue (toxic adenoma or multinodular goiter), which is more common than Graves’ disease in the elderly. 4
Scintigraphy also supplies pre‑treatment information that guides definitive therapy. 4
Routine thyroid ultrasound is not recommended as a first‑line test because it does not clarify etiology and may lead to over‑diagnosis of incidental nodules. 3
Ultrasound should be reserved for palpable neck masses or for planning radioactive iodine therapy. 3
Anti‑TSH‑receptor antibody testing is only indicated when clinical features suggest Graves’ disease, which is uncommon in this age group. 4

The principal risk of subclinical hyperthyroidism in older adults is cardiovascular complications, especially atrial fibrillation; therefore, a thorough assessment for arrhythmias, ischemic heart disease, and acute coronary syndrome is required. 5
Osteoporosis risk should be evaluated before deciding on definitive therapy, as treatment may exacerbate bone loss. 4
Document any cardiovascular symptoms (e.g., palpitations, chest pain, dyspnea) that could be triggered or worsened by excess thyroid activity. 5

Suppressed TSH < 0.1 mIU/L (as in this patient). 4
Presence of pre‑existing atrial fibrillation, other tachyarrhythmias, or ischemic heart disease. 2
Cardiovascular symptoms attributable to hyperthyroidism. 5
Established osteoporosis. 5
Large multinodular goiter (> 40–60 mL). 5

TSH 0.1–0.4 mIU/L without osteoporosis, atrial fibrillation, or cardiopathy. 5
Absence of cardiovascular risk factors or related symptoms. 4
Patient preference after shared decision‑making. 7

Radioactive iodine‑131 ablation is the first‑line definitive therapy for patients with significant cardiovascular disease, after achieving temporary medical control with antithyroid drugs. It is preferred for permanent atrial fibrillation, tachyarrhythmia, ischemic cardiopathy, or cardiovascular symptoms. 2
Low‑dose antithyroid drugs (long‑course) may be used in frail patients without serious cardiovascular disease when surgery or radioactive iodine is contraindicated or unavailable. 1
Total thyroidectomy is indicated for:
- Large goiter causing compressive symptoms. 2
- Co‑existent thyroid carcinoma. 5
- Primary hyperparathyroidism requiring concurrent surgery. 5

The European Thyroid Association advises treating all patients > 65 years with subclinical hyperthyroidism. 3
The American Thyroid Association recommends treatment for patients > 65 years when TSH < 0.1 mIU/L; for TSH 0.1–0.4 mIU/L, treatment is reserved for those with osteoporosis, atrial fibrillation, or cardiopathy. 3
The French Endocrine Society cautions that evidence is lacking that treatment reduces atrial fibrillation risk, highlights the risk of permanent hypothyroidism after definitive therapy, and notes the difficulty of achieving stable levothyroxine replacement in the elderly, with frequent TSH abnormalities. 5

Exclude non‑thyroidal causes of TSH suppression such as glucocorticoids, dopamine, or dobutamine therapy. 3
Exclude severe non‑thyroidal illness. 3
Exclude recent exposure to iodine‑containing contrast agents. 1

If surveillance is chosen, repeat TSH, free T4, and free T3 every 3–6 months initially. 3
Actively monitor for new cardiovascular complications, particularly atrial fibrillation. 1
Re‑evaluate the treatment decision if TSH becomes further suppressed or free thyroid hormone levels rise. 3